Changes made in round 3 related to the responses to specific questions
| Questions | Changes made | |
|---|---|---|
| 1 | Who has this report been written for? | Dedicated subheading ‘Who is this report for” introduced |
| 6 | What group of medicines does Bondronat belong to? | This information, formerly in the section ‘How does Bondronat work’ repositioned in the new subsection ‘What type of medicine is Bondronat’? |
| 9 | What two things were weighed up before the decision was made about whether Bondronat should be approved? | Information bulleted in revised version, to aid finding and understanding |
| 18 | When Bondronat was studied in the treatment of bone complications, which group of patients got a new bone problem first? | Simplified through new subheading of ‘What did the studies show?’ |